Liminatus Pharma, Inc.
LIMNWNasdaq
$0.05
↓ -12.9%Jul 17 close · end-of-day
Price
1Y↓ -64.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.9M
Enterprise Value
$3.4M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
8297.9%
ROIC
-229.5%
Debt / Equity
-10.9
Net Cash
-$1.4M
Return 1Y
-67.8%
Company profile
Management & directors
- Valetudo Therapeutics LlcChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
LIMNW Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.03↑ +50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$3.3M | -$3.0M |
| Net income | -$3.5M | -$10.2M |
| Diluted EPS | -$0.20 | -$0.43 |
| Operating cash flow | -$1.5M | -$10.0M |
| Free cash flow | — | -$10.0M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$909,218.00 | -$543,147.00 | -$1.9M | -$264,220.00 | -$1.1M | -$701,170.00 | -$884,211.00 | -$1.1M |
| Net income | -$961,207.00 | -$601,372.00 | -$229,752.00 | -$327,526.00 | $113,287.00 | -$1.8M | -$8.2M | -$1.1M |
| Diluted EPS | -$0.05 | -$0.03 | $2.35 | -$0.02 | $0.00 | -$0.07 | -$0.34 | -$0.03 |
| Operating cash flow | -$1.1M | -$206,119.00 | -$140,660.00 | -$159,393.00 | -$8.8M | -$600,612.00 | -$386,847.00 | -$2.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Coming soonHeadlines for LIMNW will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Valetudo Therapeutics LLC· Chief Executive Officer | J | 3,448,926 | — | — | filing |
| 2026-06-24 | Valetudo Therapeutics LLC· Chief Executive Officer | J | 4,373,603 | — | — | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.